Treatment of ankylosing spondylitis: Focus on etanercept

Biologics: Targets and Therapy

Volumn 1, Issue 1, 2007, Pages 45-51

  Frech, Tracy ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Ankylosing spondylitis; Etanercept; Tnf

Indexed keywords

EID: 79251519635     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Amor B, Santos R, Nahal R, et al. 1994. Predictive factors for the long term outcome of spondyloarthropathies. J Rheumatol, 21:1883-7.1.
2. Askling J, Klareskog L, Blomqvist P, et al. 2006. Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study. Ann Rheum Dis, 65(9):1184-7.
3. Brandt J, Listing J, Haibel H, et al. 2005. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology (Oxford), 44:342-8.
4. Braun J, Baraliakos X, Listing J et al. 2005. Decreased incidence of anterior uveitis in patients with anklosing spondylitis treated with anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum, 52:2447-51.
5. Braun J, Bollow M, Neure L, et al. 1995. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum, 38:499-505.
6. Braun J, Bollow M, Eggens U, et al. 1994. Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroilitis in spondyloarthopathy patients. Arthritis Rheum, 37:1039-45.
7. Braun J, van der Heijde D, Dougados M. 2002. Staging of patients with ankylosing spondylitis: a preliminary proposal. Ann Rheum Disease, 61:19-23.
8. Calin A, Dijkmans B, Emery P, et al. 2004. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis, 63:1594-600.
9. Chen J, Liu C. 2005. Sulfasalazine for anklosing spondylitis. The Cochrane Database of Systematic Reviews, 18:CD004800
10. Chen J, Liu C, Lin J. 2006. Methotrexate for ankylosing spondylitis. The Cochrane Database Systematic Reviews, 4:CD004524.
11. Clegg DO, Reda DJ, Adbellatif M. 1999. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondyloarthropathies: a Department of Veterans Affairs Cooperative Study. Arthritis Rheum, 42:2325-9.
12. Colbert, RA. 2000. HLA-B27 misfolding: a solution to the spondyloartopathy conundrum? Mol Med Today, 6:224-30.
13. Dagfinrud H, Kvien T, Hagen K. 2005. The Cochrane review of physiotherapy interventions for ankylosing spondylitis. J Rheumatol, 32:1899-906.
14. Davis JC Jr, van der Heijde D, Braun J, et al. 2003. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis a randomized, control trial. Arthritis Rheum, 48:3230-6.
15. Davis JC Jr, van der Heijde D, Braun J, et al. 2005. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis, 64:1557-62.
16. De Keyser F, Baeten D, Van den Bosch F. 2004. Structrure-modifying capacity of anti-tumour necrosis factor-αtherapy in ankylosing spondylitis. Drugs, 64:2793-811.
17. De Keyser F, Elewaut D, De Vos M, et al. 1998. Bowel-inflammation and the spondyloarthopathies. Rheum Dis Clin North Am, 24:785-813.
18. Desai SB, Furst DE. 2006. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol, 20:757-90.
19. Dougados M, vam der Linden S, Leirisalo-Repo M, et al. 1995 Sulfasalazine in the treatment of spondyloarthopathy. A randomized, multi-center, double-blind, placebo-controlled study. Arthritis Rheum, 38:618-27.
20. Ebringer A, Wilson C. 2000. HLA molecules, bacteria and autoimmunity. J Med Microbiol, 49:305-11.
21. Ellerin T, Rubin, R, Weinblatt M. 2003. Infections and anti-tumor necrosis factor α therapy. Arthritis Rheum, 48:3013-22.
22. Feltkamp T, Ringrose J. 1998. Acute anterior uveitis and spondyloarthopathies. Curr Opin Rheumatol, 10:314-8.
23. Fox MW, Onofrio BM, Kilgore JE. 1993. Neurological complications of ankylosing spondylitis. J Neurosurg, 78:871-8.
24. Galor A, Perez VL, Hammel JP, et al. 2006. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology, 113:2317-23.
25. Giles J, Bathon J. 2004. Serious infections associated with anticytokine therapies in the rheumatic diseases. J Intensive Care Med, 19:320-34.
26. Gorman JD, Sack KE, Davis JC Jr. 2002. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med, 346:1349-56.
27. Gran J, Skomsvoll J. 1997. The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol, 36:766-71.
28. Gratacos J, Collado A, Filella X et al. 1994. Serum cytokines (Il-6, TNF alpha, IL-1 beta and IFN gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol, 33:927-31.
29. Han C, Robinson DW Jr, Hackjett MV, et al. 2006. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol, 33:2167-72.
30. Hoffman IE, Demetter P, Peeters M, et al. 2003. Anti-saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy. Ann Rheum Dis, 62:455-9.
31. Huang F, Wei JC, Breban M. 2002. Thalidomide in ankylosing spondylitis. Clin Exp Rheumatol, 20 (Suppl 28):S158-61.
32. Lopez de Castro JA. 2007. HLA-B27 and the pathogenesis of spondyloarthropathies. Immunol Lett, 108:27-33.
33. Maksymowych WP, Jhangri GS, LeClereq S, et al. 1998. An open study of pamidronate in the treatment of refractory ankylosing spondylitis. J Rheumatol, 25:714-7.
34. Marzo-Ortega H, McGonagle D, OConnor P, et al. 2001. Efficacy of etanercept in the treatment of the enethesal pathology in resistant spondyloarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum, 44:2112-7.
35. Mielants H, Veys EM, De Vos M, et al. 1995. The evolution of the spondyloarthopathies in relation to gut histology. III: relation between gut and joint. J Rheumatol, 22:2266-78.
36. Mohan N, Edwards ET, Cupps TR, et al. 2001. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum, 44:2862-9.
37. Nash PT, Florin TH. 2005. Tumour necrosis factor inhibitors. Med J Aust, 183:205-8.
38. Ormerod LP. 2004. Assessing risk and managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF alpha treatment. Cytokine, 28:179-81.
39. Quismorio FP Jr. 2006. Pulmonary involvement in ankylosing spondylitis. Curr Opin Pulm Med, 12:342-5.
40. Ramos-Remus C, Gomez-Vargas A, Hernandez-Chavez A, et al. 1997. Two year follow-up of anterior and vertical atlantoaxial subluxation in ankylosing spondylitis. J Rheumatol, 24:507-10.
41. Reveille JD. 2001. HLA B27 and genetiv predisposing factors in spondyloarthropathies. Curr Opin Rheumatol, 13:265-72.
42. Rudwaleit M, Metter A, Listing J, et al. 2006. Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum, 54:569-78.
43. Salliot C, Gossec L, Ruyssen-Witrand, et al. 2007. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford), 46:327-34.
44. Sieper J, Rudwaleit M, Khan M, et al. 2006. Concepts and epidemiology of spondyloarthritis. Best Pract Res Clin Rheumatol, 20:401-17.
45. Spanakis E, Sidiropouloos P, Papadakis, J, et al. 2006. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol, 33:2440-6.
46. Tan AL, Marzo-Ortega H, O'Connor P, et al. 2004. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis, 63:1041-45.
47. Van der Lin S, Valkenburg H, Cats A. 1984. Evaluation of diagnositic criteria for ankylosing spondylitis: a proposal for modification of the New York Criteria. Arthritis Rheum, 27:361-8.
48. Zochling J, van der Heijde D, Burgos-Vargas R, et al. 2006a. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis, 65:442-52.
49. Zochling J, van der Heijde D, Dougados M, et al. 2006b. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASA/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis, 65:423-32.